EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comprehensive circulating tumor DNA mutation profiling via CAPP-Seq liquid biopsy for cervical cancer

Naoyuki Iwahashi, Tomoko Noguchi, Kazuko Sakai, Tamaki Yahata, Kaho Nishioka, Megumi Fujino, Shinichiro Takeda, Nobuhiko Suzuki, Kazuto Nishio, Kazuhiko Ino

International Journal of Clinical Oncology · 2026-05 · 31 (5) · 878-889

DOI: 10.1007/s10147-026-03006-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 10.03.2026. Verfasst von Naoyuki Iwahashi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, School of Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan. naoyuki@wakayam…. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Circulating Tumor DNA, Biomarkers, Tumor. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Liquid biopsy using circulating tumor DNA (ctDNA) is a minimally invasive approach for detecting tumor-associated genomic alterations. Although ctDNA analysis has been widely explored in solid tumors, its application to cervical cancer remains limited. Cancer personalized profiling by deep sequencing (CAPP-Seq) enables sensitive ctDNA profiling via molecular barcoding and digital error suppression.

Methods

We evaluated the feasibility of ctDNA-based mutation profiling in cervical cancer using the CAPP-Seq platform by analyzing plasma samples from 38 patients.

Results

The cohort included three patients with stage I disease, nine with stage II, 19 with stage III, and seven with stage IV. Somatic gene alterations were detected in 33 of the 38 cases (87%), including squamous cell carcinoma (27/29 [93%]) and adenocarcinoma (6/9 [67%]). Non-synonymous mutations were identified in 23 patients (59%), with PIK3CA being the most frequently mutated gene [13/38 (34%)]. Copy number gains of EGFR , MET , and ERBB2 were observed in 24%, 11%, and 5% of cases, respectively. The median blood tumor mutational burden was 17.7 mutations/Mb, and 50% of the patients exhibited a hypermutated phenotype. In a subset of four patients who received concurrent chemoradiotherapy, longitudinal changes in ctDNA mutation profiles between pre- and post-treatment samples were associated with treatment response.

Conclusions

This study demonstrates the feasibility of ctDNA-based mutation profiling using CAPP-Seq in cervical cancer, with a high detection rate of tumor-associated genomic alterations across histological subtypes. ctDNA analysis may represent a minimally invasive approach for the molecular characterization and disease monitoring of cervical cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsCirculating Tumor DNABiomarkers, TumorHumansFemaleLiquid BiopsyMiddle AgedHigh-Throughput Nucleotide SequencingMutationAgedAdultClass I Phosphatidylinositol 3-KinasesDNA Mutational AnalysisCarcinoma, Squamous Cell

Stichwörter der Autor:innen

Cervical cancerCirculating tumor DNAComprehensive genomic profilingLiquid biopsy

Substanzen

Circulating Tumor DNABiomarkers, TumorClass I Phosphatidylinositol 3-KinasesPIK3CA protein, human

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, School of Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan. naoyuki@wakayama-med.ac.jp.
  • Department of Obstetrics and Gynecology, School of Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
  • Faculty of Medicine, Department of Genome Biology, Kindai University, Osaka, Japan.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Iwahashi, N., Noguchi, T., Sakai, K., Yahata, T., Nishioka, K., Fujino, M., Takeda, S., Suzuki, N., Nishio, K., & Ino, K. (2026). Comprehensive circulating tumor DNA mutation profiling via CAPP-Seq liquid biopsy for cervical cancer. International Journal of Clinical Oncology, 31(5), 878-889. https://doi.org/10.1007/s10147-026-03006-1

Vancouver

Iwahashi N, Noguchi T, Sakai K, Yahata T, Nishioka K, Fujino M, et al. Comprehensive circulating tumor DNA mutation profiling via CAPP-Seq liquid biopsy for cervical cancer. International Journal of Clinical Oncology. 2026;31(5):878-889. doi:10.1007/s10147-026-03006-1

BibTeX
@article{Iwahashi2026,
  author = {Iwahashi, Naoyuki and Noguchi, Tomoko and Sakai, Kazuko and Yahata, Tamaki and Nishioka, Kaho and Fujino, Megumi and Takeda, Shinichiro and Suzuki, Nobuhiko and Nishio, Kazuto and Ino, Kazuhiko},
  title = {Comprehensive circulating tumor DNA mutation profiling via CAPP-Seq liquid biopsy for cervical cancer},
  journal = {International Journal of Clinical Oncology},
  year = {2026},
  volume = {31},
  number = {5},
  pages = {878--889},
  doi = {10.1007/s10147-026-03006-1}
}
Kostenlos starten →